ImmunityBio Inc. has announced updated Phase 2 clinical results from the QUILT 3.078 trial (NCT06061809) evaluating a chemotherapy-free combination immunotherapy regimen, ANKTIVA® plus CAR-NK, in patients with second-line recurrent or progressive glioblastoma (GBM) and in patients treated under single-patient INDs across first- to third-line disease. As of January 22, 2026, the primary endpoint of median overall survival has not yet been reached, with 19 of 23 enrolled patients alive. Fourteen patients have evaluable data, with the longest survival from time of disease recurrence reaching 12 months and ongoing. The study reports that baseline mean absolute lymphocyte count $(ALC)$ was 0.9 x 10^3/uL, and ALC increased to ≥ 1.4 x 10^3/uL within one treatment cycle (p <0.001, N=14). Statistically significant increases in ALC from baseline were observed at all assessments through 20 weeks. Three treatment-related serious adverse events were reported among 41 GBM patients across all cohorts. Randomized controlled trials in both first-line and second-line glioblastoma are in development. The results have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief on January 23, 2026, and is solely responsible for the information contained therein.